Pharmacogenomics Market to Hit $8.87 Billion by 2033, Driven by Personalized Medicine & Genetic Testing

Leander, Texas and Tokyo, Japan - Dec.05.2025
As per DataM intelligence research report" The global pharmacogenomics market was valued at US$ 3.59 Billion in 2023. The market size reached US$ 3.92 Billion in 2024 and is expected to reach US$ 8.87 Billion by 2033, growing at a CAGR of 9.8% during the forecast period 2025-2033." Personalized therapy and genetic testing integration are driving growth in pharmacogenomics applications.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/pharmacogenomics-market?Prasad

United States: Recent Industry Developments

✅ In November 2025, The FDA approved a new label update for Clopidogrel requiring CYP2C19 genotyping The update mandates testing to ensure heart patients can metabolize the blood thinner effectively It enforces a pharmacogenomic standard of care for U.S. cardiology patients

✅ In September 2025, Thermo Fisher Scientific launched a "PharmacoScan" array covering 5,000+ variants The comprehensive panel allows U.S. labs to test for gene-drug interactions across multiple therapeutic areas It enables broad implementation of pre-emptive pharmacogenomic screening

✅ In August 2025, CVS Health piloted a "Precision Medicine" program offering pharmacogenomic testing at retail clinics The program helps patients understand which antidepressants or pain meds work best for their DNA It makes personalized medicine accessible to the general U.S. public

✅ In July 2025, A major U.S. psychiatric association updated its guidelines to recommend PGx testing for depression The guidelines endorse testing before starting SSRIs to avoid adverse reactions It integrates pharmacogenomics into mainstream U.S. mental health care

Japan: Recent Industry Developments

✅ In December 2025, Toppan and RIKEN launched a "Digital Twin" project for drug response prediction The project uses pharmacogenomic data to simulate how a patient will metabolize drugs virtually It advances the field of computational personalized medicine in Japan

✅ In November 2025, The PMDA (Japan's FDA) approved a new companion diagnostic for a lung cancer drug The test identifies a specific genetic mutation prevalent in the Japanese population It ensures Japanese patients receive the most effective targeted therapy

✅ In October 2025, Tohoku University Hospital started a "Pre-emptive PGx" clinical trial for elderly patients The trial tests patients for multi-drug interactions before they are prescribed polypharmacy It aims to reduce adverse drug events in Japan's aging society

✅ In September 2025, a Japanese startup, Genomedia, released an AI tool for interpreting PGx data in electronic health records The tool alerts doctors to potential gene-drug conflicts at the point of prescribing It supports safer prescribing practices in Japanese clinics

Pharmacogenomics Market: Drivers
The pharmacogenomics market is expanding as personalized medicine gains traction in improving therapeutic efficacy and minimizing adverse drug reactions. Pharmacogenomic testing analyzes genetic variations to guide drug selection, dosing, and treatment strategies. Technological advancements in genomics, high-throughput sequencing, and bioinformatics are enhancing accuracy and accessibility. Rising prevalence of chronic diseases, oncology treatments, and precision therapies is driving adoption. Increasing awareness among healthcare providers and patients further supports market growth.

Collaborations among biotech firms, pharmaceutical companies, and research institutions are accelerating pharmacogenomic test development and clinical integration. Growth in companion diagnostics, gene-based therapies, and precision medicine programs is expanding applications. Integration with electronic health records, AI analytics, and telehealth platforms enhances clinical decision-making. Regulatory support for personalized medicine initiatives strengthens market potential. With ongoing innovation and growing emphasis on precision healthcare, the pharmacogenomics market is poised for sustained expansion.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/pharmacogenomics-market?Prasad

Pharmacogenomics Market: Major Players
Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Company, Biomerieux, Bio-Rad Laboratories Inc., Illumina, Eurofins Scientific, Pacific Biosciences of California Inc., Qiagen, and Thermo Fisher Scientific Inc., among others.

Segment Covered in the Pharmacogenomics Market:
By Product and Service Type
Kits & reagents lead with 40% share, driven by demand for reliable sample preparation, biomarker detection, and high-throughput pharmacogenomic testing. Instruments hold 30%, supported by advanced sequencing platforms, PCR machines, microarray readers, and mass spectrometers enabling precision analysis. Software & services account for 30%, providing bioinformatics, data interpretation, and consulting for personalized medicine applications. Adoption across product and service types enhances workflow efficiency, accuracy, and clinical decision-making. Continuous innovation in assay kits and instrumentation is expanding market capabilities.

By Technology
DNA sequencing dominates with 38% share, powering genome analysis, mutation detection, and pharmacogenomic profiling. Polymerase Chain Reaction (PCR) holds 22%, widely used for gene amplification, diagnostics, and drug response testing. Microarray technology captures 15%, enabling high-throughput genotyping and expression analysis. Electrophoresis and mass spectrometry contribute 15%, supporting protein and nucleic acid characterization. Other technologies account for 10%, including emerging analytical platforms improving throughput, sensitivity, and precision.

By Application
Drug discovery leads with 35% share, as pharmacogenomics enables target identification, biomarker validation, and preclinical testing. Personalized medicine holds 30%, driven by tailored therapies based on genetic profiles for optimal efficacy and safety. Clinical research accounts for 25%, supporting pharmacokinetic/pharmacodynamic studies and clinical trial stratification. Other applications contribute 10%, including nutrigenomics, adverse drug reaction prediction, and diagnostic research. Adoption is fueled by precision medicine initiatives and regulatory support for genomics-based therapies.

By Disease Area
Oncology dominates with 32% share, driven by targeted therapies, immunotherapy personalization, and biomarker-guided treatment selection. Cardiovascular disorders hold 20%, supported by pharmacogenomic testing for anticoagulants, statins, and hypertension therapies. Neurological diseases account for 18%, focusing on drug response prediction in epilepsy, Alzheimer's, and Parkinson's disease. Infectious diseases hold 12%, enabling antiviral and antibacterial personalized therapy development. Mental health and other disease areas represent 18%, with applications in psychiatry, rare genetic disorders, and chronic disease management.

Regional Analysis
North America leads with 36% share, supported by strong pharmaceutical R&D, advanced genomics infrastructure, and government funding in precision medicine initiatives.

Europe holds 27%, driven by Germany, the UK, and France with strong clinical research networks, genomics programs, and healthcare innovation.

Asia Pacific captures 28%, expanding rapidly due to China, Japan, South Korea, and India investing in sequencing facilities, bioinformatics, and pharmacogenomic services.

South America holds 5%, led by Brazil and Argentina with growing clinical genomics adoption and biotechnology investments.

Middle East & Africa account for 4%, with adoption focused on research centers, oncology programs, and personalized medicine initiatives in GCC countries and South Africa.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=pharmacogenomics-market
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?Prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.